← All trials
NCT05744739
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 29, 2023
- Primary completion
- Apr 23, 2029
- Completion date
- Apr 23, 2030
- First posted
- Feb 27, 2023
- Last posted
- Nov 2, 2023
- Enrollment
- 15
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Northwestern UniversityLead sponsor
- Effector TherapeuticsCollaborator
- National Cancer Institute (NCI)Collaborator
- Northwestern UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.